DMK
LXRX icon

David M. Knott’s Lexicon Pharmaceuticals LXRX Stock Holding History

David M. Knott’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-29,800
Closed -$90K – 120
2019
Q3 		$90K Sell
29,800
-200
-0.7% -$619 0.04% 98
2019
Q2 		$189K Hold
30,000
– – 0.08% 76
2019
Q1 		$167K Buy
+30,000
New +$182K 0.07% 77

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

David M. Knott's LXRX Position: Q4 2019 in Review

David M. Knott sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2019, closing a stake of 29,800 shares — an estimated $90K sold.

David M. Knott first reported a position in LXRX in Q1 2019 and held it in 3 quarters. The position peaked at $189K in Q2 2019. 115 funds tracked by Wall St. Rank hold LXRX as of Q4 2019.

  • David M. Knott reported no remaining Lexicon Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • David M. Knott sold 29,800 Lexicon Pharmaceuticals shares in Q4 2019, an estimated $90K.
  • David M. Knott first reported a position in Lexicon Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • David M. Knott's Lexicon Pharmaceuticals position peaked at $189K in Q2 2019.
  • 115 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2019.

Based on David M. Knott's 13F filing for Q4 2019, filed 14 Feb 2020.